argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG)
Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback
Enrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP)
Announced interim data from Phase 2 CULMINATE trial of cusatuzumab in development with Janssen
Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements fro
Six test cases have been done in Philippines by team at King s College London
Australia, Canada, the United States and Britain found to have fathered children
The research technology that was used to find California s Golden State Killer
It comes in the wake of the 2011 Oxfam scandal that found staff had engaged in sexual misconduct with victims of the 2010 Haitian earthquake